Abstract

Sarepta Therapeutics will report quarterly results on May 06, 2026, Post Market, with investor attention centered on revenue trajectory, margin stabilization, and progress across gene therapy and exon-skipping franchises.

Market Forecast

Consensus points to current-quarter revenue of 474.15 million US dollars, adjusted EPS of 0.99, and EBIT of 105.98 million US dollars; year-over-year, revenue is expected to decline by 30.61%, while EPS and EBIT are projected to increase by 204.75% and 292.68%, respectively. Guidance on gross profit margin and net margin for the quarter is not provided, but the mix remains predominantly product-driven, with product sales historically representing over four-fifths of total revenue.

The company’s main business is anchored by product sales supported by its Duchenne muscular dystrophy therapies and partnered commercialization outside the United States; momentum will hinge on execution in core markets, milestones from recent launches, and maintaining treatment continuity. The most promising segment is the gene therapy franchise; product revenue was 369.61 million US dollars last quarter (83.45% of total), and while segment-specific year-over-year data is not disclosed, program updates and recent international access suggest near-term catalysts.

Last Quarter Review

In the last reported quarter (fiscal Q4 2025), Sarepta Therapeutics delivered revenue of 442.93 million US dollars, a gross profit margin of -63.47%, GAAP net profit attributable to the parent company of -283.00 million US dollars, a net profit margin of -63.86%, and adjusted EPS of -3.93, with year-over-year EPS growth at -362.00%.

A notable financial highlight is that revenue exceeded consensus by 51.01 million US dollars, reflecting stronger-than-expected sales despite an EPS miss versus estimates. Main business performance remained concentrated in product revenue of 369.61 million US dollars and collaboration revenue of 73.33 million US dollars; year-over-year detail by segment was not disclosed, but total revenue declined 32.73% year-over-year.

Current Quarter Outlook

Main Business: Product Sales and Execution Across Duchenne and Exon-Skipping Therapies

Product sales are expected to remain the primary driver this quarter, consistent with last quarter’s 83.45% revenue contribution from the product portfolio. The revenue forecast of 474.15 million US dollars, despite a projected year-over-year decline of 30.61%, implies improved profitability metrics as operating leverage materializes in manufacturing and logistics, reflected in the consensus EPS and EBIT expansion. The mix of sales across Duchenne muscular dystrophy treatments, including exon-skipping therapies, will be pivotal, and inventory management along with treatment initiation rates will influence realized revenue.

Operationally, delivery cadence, patient onboarding, and treatment adherence are essential to translating demand into recognized revenue. The company’s commercialization outside the United States via partners enhances coverage breadth, but coordination on supply, reimbursement, and post-marketing surveillance will determine the pace of international sales contribution this quarter. Further, sustaining prescriber confidence and minimizing therapy interruptions in the clinical community are critical to smoothing revenue volatility, especially as label updates or safety protocols evolve.

Profitability improvement projections, despite lower revenue year-over-year, suggest anticipated cost relief or a more favorable product mix relative to last year’s elevated expense base. The gap between EPS and revenue growth signals potential efficiency gains in operating expense containment, manufacturing normalization, and lower non-operating charges relative to Q4 2025. Maintaining this trajectory will require vigilant cost discipline and deliberate prioritization of spend across late-stage programs and launch support.

Most Promising Business: Gene Therapy Franchise and International Milestones

The gene therapy franchise sits at the forefront of growth potential, underpinned by deeper clinical and commercialization efforts and new market entries. Early in the quarter, international access progressed: Roche’s Chugai launched Elevidys in Japan for children ages three to under eight, which triggers a 40.00 million US dollar milestone associated with the first commercial sale in Japan. This milestone and early commercial momentum can contribute meaningfully to recognized revenue, even as first-half US uptake may be tempered by evolving practice patterns and heightened monitoring protocols.

In the United States, the program is supported by a study evaluating an enhanced immunosuppression regimen (including prophylactic sirolimus) in non-ambulatory individuals, with approximately 25 participants expected to enroll. The trial’s primary endpoints on acute liver injury incidence and micro-dystrophin expression are aimed at strengthening the safety and biomarker profile, which, if favorable, may enhance prescriber confidence and inform utilization in broader patient cohorts. These clinical steps are crucial for maintaining the franchise’s trajectory and sustaining patient access while addressing risk management in gene therapy.

Investor focus this quarter will be on the interplay between Japanese commercialization, US treatment patterns, and clinical updates. Even if near-term US revenue from the program is moderate, demonstration of consistent safety protocols and gradual uptake could prime the franchise for improved second-half dynamics. The forecasted EPS and EBIT expansion relative to last year suggests improved cost absorption and the benefit of milestone revenues in the quarter; aligning supply, reimbursement, and patient selection criteria will be central to realizing the franchise’s full potential.

Factors Most Impacting the Stock: Regulatory Progress, Safety Perception, and Earnings Quality

Regulatory and label milestones remain central. The company has stated that it plans to submit supplemental new drug applications to convert accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals by the end of April. This timeline places initial regulatory interactions squarely within the current quarter’s narrative and may influence sentiment by signaling pathway clarity and durability of revenue from the exon-skipping portfolio. While topline phase 3 results showed numerical trends without reaching statistical significance on the primary endpoint, the reported safety profile—largely mild to moderate adverse events—will be carefully weighed by prescribers and investors.

Safety perception, notably in gene therapy, carries significant consequence for adoption rates and label breadth. The ongoing study of enhanced immunosuppression is designed to mitigate liver-related risks associated with adeno-associated virus gene therapies, aiming to reinforce confidence in the treatment protocol. Clinician feedback, patient selection criteria, and adherence to monitoring algorithms will be scrutinized this quarter, as modest improvements in safety confidence could translate into steadier treatment initiation trends and narrower variance in weekly bookings.

Earnings quality is the third focal point, given the forecasted improvement in EPS and EBIT against a declining year-over-year revenue base. This dynamic implies margin recovery or a normalization of operating expenses relative to the prior quarter’s elevated cost structure. Investors will examine the sustainability of these improvements—specifically whether operating gains stem from one-time events (e.g., milestones) or reflect enduring efficiencies in manufacturing, distribution, and SG&A. A cleaner quarter with fewer transitory items, alongside stable cash generation metrics and visibility on second-half demand, will be instrumental in anchoring valuation and price target assumptions.

Analyst Opinions

The majority of institutional views gathered in the current period reflect neutral or hold stances, emphasizing balanced risk-reward and the need for clearer visibility on uptake and regulatory trajectories. RBC maintained a Sector Perform rating with a price target of 19.00 US dollars on April 07, 2026, citing a pragmatic posture on near-term revenue softness and the need for sustained evidence of demand stabilization in core therapies. Barclays kept a Hold rating with a 20.00 US dollars price target, underscoring caution around first-half revenue cadence and the importance of safety and label clarity in shaping prescriber behavior. Bernstein maintained a Hold rating at 20.00 US dollars, highlighting the valuation’s alignment with current execution and safety considerations. Cantor Fitzgerald reiterated a Hold rating with a price target of 21.00 US dollars, noting that greater visibility on regulatory filings and consistent commercial performance would be needed to shift stance.

The neutral camp generally converges on several themes. First, early 2026 revenue may be constrained by measured uptake patterns and careful patient selection, consistent with the company’s own forecast of a 30.61% year-over-year revenue decline. Second, profitability is expected to improve due to operating normalization and milestone recognition, reflected in projected EPS growth of 204.75% and EBIT growth of 292.68%. Third, successful filings to convert accelerated approvals for Amondys 45 and Vyondys 53 to traditional approvals could be an important linchpin for sustaining long-term revenue reliability; institutions prefer to see steps completed and initial regulatory feedback before revising ratings.

Neutral-rated institutions also point to the need for demonstration of demand resilience into the second half of 2026. Although international commercialization via partners—such as the launch in Japan—adds breadth to the revenue base and delivers milestones, converting these advances into consistent, predictable product sales across geographies remains central to rating upgrades. The collective view implies that near-term upside drivers exist, but evidence must accrue on safety protocol effectiveness, smoother patient access, and dependable prescriber adoption to substantiate a more constructive stance.

Price targets in the neutral group cluster in the high-teens to low-twenties, mirroring the perception of tempered upside until execution milestones are clearly met. These institutions are watching for confirmation that margin improvement is not solely one-off. They are also monitoring clinical updates—from the enhanced immunosuppression study and other program readouts—to gauge whether safety confidence and label evolution can materially recalibrate utilization. Altogether, the majority neutral posture is consistent with the market’s emphasis on disciplined validation of both commercial momentum and regulatory progression, even as forecasted profitability metrics suggest a more favorable near-term earnings profile.